Control of Risk Factors in and Treatment of Patients With Coronary Heart Disease: The TRECE Study

Vicente Bertomeu,a Alberto Cordero,a Juan Quiles,a Pilar Mazón,b Joaquín Aznar,c and Héctor Buenod

aDepartamento de Cardiología, Hospital Universitario de San Juan, San Juan de Alicante, Alicante, Spain
bDepartamento de Cardiología, Hospital Santiago de Compostela, Santiago de Compostela, A Coruña, Spain
cDepartamento de Cardiología, Hospital Nuestra Señora de Gracia, Zaragoza, Spain
dDepartamento de Cardiología, Hospital Gregorio Marañón, Madrid, Spain

BRIEF REPORT

The aim of the TRECE study was to describe treatment in patients with coronary heart disease (CHD). It was an observational, cross-sectional, multicenter study of patients who were treated in either an internal medicine (n=50) or cardiology (n=50) department, or in primary care (n=100) during 2006. The patients' history, risk factors, and treatment were recorded, and noncardiac disease was evaluated using the Charlson index. Optimal medical treatment (OMT) was regarded as comprising combined administration of antiplatelet agents, statins, beta-blockers, and renin-angiotensin-aldosterone system blockers. In total, data on 2897 patients were analyzed; their mean age was 67.4 years and 71.5% were male. Overall, 25.9% (95% confidence interval, 25.6-26.2) received OMT. Multivariate analysis showed that prescription of OMT was independently associated with hypertension, diabetes, current smoking, myocardial infarction, and angina. In contrast, nonprescription of OMT was associated with atrial fibrillation, chronic obstructive pulmonary disease and a Charlson index =4. The main findings were that few CHD patients were prescribed OMT and that its prescription was determined by the presence of symptoms and comorbid conditions.

Key words: Optimal medical treatment. Limitations. Coronary heart disease

Control de los factores de riesgo y tratamiento de los pacientes con cardiopatía isquémica: registro TRECE

El registro TRECE describe el tratamiento de pacientes con cardiopatía isquémica (CI). Estudio transversal, observacional y multicéntrico de pacientes atendidos en medicina interna (n = 50), cardiolopatía (n = 50) y atención primaria (n = 100) en 2006. Se registraron antecedentes, factores de riesgo y tratamientos; la afección extracardíaca se evaluó mediante el índice de Charlson. Se consideró tratamiento médico óptimo (TMO) la prescripción conjunta de antiagregación, bloqueadores beta, estatinas y bloqueo del sistema renina-angiotensina-aldosterona. Se analizó a 2.897 pacientes, con una media de edad de 67,4 años; el 71,5% eran varones. El TMO se realizó en el 25,9% (intervalo de confianza del 95%, 25,6-26,2) de los pacientes. El análisis multivariable mostró que la hipertensión arterial, la diabetes, el tabaquismo, el infarto previo y la angina conllevaron mayor prescripción de TMO; la fibrilación auricular, la enfermedad pulmonar obstructiva crónica y el índice de Charlson = 4 se relacionaron con menor prescripción. La principal conclusión es que la prescripción del TMO de pacientes con CI es baja y se ve determinada por los síntomas y comorbilidades.

Palabras clave: Tratamiento médico óptimo. Limitaciones. Cardiopatía isquémica.

INTRODUCTION

The number of patients with coronary heart disease (CHD) is increasing1,2 and the medical treatment and management of associated risk factors can result in important prognostic improvements for these patients.3,5 Combined treatment with antiplatelet aggregators, beta-blockers, statins and renin-angiotensin-aldosterone system block with angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor antagonists (ARA-II) is considered to be the optimal medical treatment (OMT).3,5
The Spanish Society of Cardiology sections on Arterial Hypertension, Ischemic Heart Disease and Clinical and Extrahospital Cardiology undertook the TRECE Study (TRatamiento de la Enfermedad Coronaria en España—Treatment of Coronary Heart Disease in Spain) in order to describe the control and prescription of the OMT of patients with CHD.

**METHODS**

**Study Design**

We undertook a descriptive, cross-sectional multicenter study involving specialists from 20 randomly selected health care areas. A total of 200 physicians took part (50 specialists in cardiology, 50 in internal medicine, and 100 primary care physicians) and 3000 consecutive patients during the first quarter of 2006; 103 patients were excluded as their data were either incomplete or contradictory. The protocol was approved by the Ethics Committee of the Hospital Universitario de San Juan, Alicante. The inclusion criteria were: a confirmed clinical diagnosis of stable chronic angina, chest pain with a positive stress test, a prior diagnosis of acute coronary syndrome, myocardial infarction, or unstable angina. The patients could have more than one of the inclusion criteria, which were obtained from the clinical history or medical records provided by the patients.

Optimal medical treatment was considered to be the joint prescription of antiplatelet aggregators, beta-blockers, statins and ACE inhibitors or ARA-II. Hypertension was considered to controlled if it was <140/90 mm Hg or <130/80 mm Hg in diabetics. Hypertension was considered to be controlled if it was <140/90 mm Hg or <130/80 mm Hg in diabetics.6 The resting heart rate (HR) was considered to be controlled if it was <70 bpm during the physical examination or on the electrocardiogram (ECG) during the office visit.7 Low-density lipoprotein (LDL) concentrations <100 mg/dL were accepted to represent controlled dyslipidemia.8 The control of diabetes mellitus was only done by glycemia levels <108 mg/dL; a baseline glycemia <100 mg/dL was considered to be controlled.9 The diagnosis of atrial fibrillation (AF) was only done by ECG. Chronic obstructive pulmonary disease (COPD) was recorded if a diagnosis of COPD existed on the clinical history or the patient was taking specific medication. The joint analysis of the comorbid conditions was done using the Charlson index, adapted to patients with CHD. A high comorbidity rate was considered to be a Charlson score of ≥4.10

The data were analyzed using the SPSS 15.0 statistical program (SPSS Inc, Chicago, IL). Comparisons between means were analyzed using the Student t test. The multivariate analysis was done using logistic regression and the results are presented, after adjustment for age and sex, in the form of the odds ratio (OR) with the 95% confidence interval (CI). Statistical significance was set at P≤.05.
RESULTS

The characteristics of the sample are shown in Table 1. The control of the risk factors was generally poor and significantly worse in those patients who reported having angina (Figure). The patients who were receiving treatment with beta-blockers had a lower resting HR than those who were not receiving this treatment (67.3 bpm vs 72.8 bpm; *P* <.01), although only 61.4% (95% CI, 60.8-70) had a HR<70 bpm; no differences were found in the HR of the patients who were being treated with calcium antagonists.
patients with CHD had their resting HR controlled and that, in general clinical practice, beta-blockers achieve a poor control. The presence of noncardiac involvement is an important predictor of mortality in patients with CHD; the Charlson index is useful to identify those patients with a worse prognosis and our data demonstrate that the index identifies patients with a lower prescription of OMT.

Various reasons may explain the low compliance of OMT in the patients with CHD. A low degree of awareness of the aims of control of risk factors has been reported in Spain. The data from the TRECE Study have enabled us to identify that AF, COPD and comorbid conditions are the main limiting factors for the therapeutic implementation of OMT. Concerning AF, the underuse of antiplatelet aggregators seems to be related with the 60% anticoagulation, although the poor use of beta-blockers was also notable. Severe forms of COPD are a relative contraindication to the use of beta-blockers, though these drugs reduce the number of readmissions; the use of cardioselective beta-blockers, calcium antagonists or selective inhibitors of the sinus node If current, such as ivabradine, are effective alternatives.

**Study Limitations**

As this was a multicenter study, the collection of data was simplified and did not include the measurement of glycohemoglobin; this measurement has been used in previous studies and may have underestimated the awareness of control of diabetes.

**DISCUSSION**

The TRECE Study shows that the control of risk factors in patients with CHD is generally poor, especially in those who have symptoms of angina pectoris; and furthermore, the prescription of the OMT was low and determined by the accompanying disorders. The sample of patients included in the TRECE Study was very similar to that of other international and national surveys.

The low percentage of patients who were controlled is a constant finding in the many studies available. Our results also show that only half the

### Table 3. Relation Between Various Clinical Characteristics and the Prescription of Optimal Medical Treatment

<table>
<thead>
<tr>
<th>Clinical Variable</th>
<th>OR</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>1.95</td>
<td>1.55-2.45</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>1.4</td>
<td>1.14-1.72</td>
<td>.01</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>1.23</td>
<td>1.1-1.53</td>
<td>.03</td>
</tr>
<tr>
<td>Current smoker</td>
<td>1.5</td>
<td>1.08-2.07</td>
<td>.01</td>
</tr>
<tr>
<td>Stroke</td>
<td>1.19</td>
<td>0.86-1.65</td>
<td>.3</td>
</tr>
<tr>
<td>Peripheral arterial disease</td>
<td>0.87</td>
<td>0.66-1.16</td>
<td>.37</td>
</tr>
<tr>
<td>Heart failure</td>
<td>1.81</td>
<td>1.39-2.37</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>COPD</td>
<td>0.65</td>
<td>0.48-0.87</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>0.23</td>
<td>0.14-0.36</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Renal failure*</td>
<td>1.03</td>
<td>0.81-1.32</td>
<td>.81</td>
</tr>
<tr>
<td>Angina pectoria</td>
<td>1.6</td>
<td>1.27-2.04</td>
<td>.01</td>
</tr>
<tr>
<td>Stable angina</td>
<td>1.09</td>
<td>0.86-1.38</td>
<td>.46</td>
</tr>
<tr>
<td>Prior myocardial infarction</td>
<td>1.6</td>
<td>1.26-2.02</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Non-Q wave myocardial infarction</td>
<td>1.27</td>
<td>0.95-1.7</td>
<td>.10</td>
</tr>
<tr>
<td>Unstable angina</td>
<td>1.07</td>
<td>0.86-1.34</td>
<td>.53</td>
</tr>
</tbody>
</table>

CI indicates confidence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio.

*Glomerular filtration rate <60 mL/min.

### REFERENCES


